Advertisement
ALC vs TMO
Which Stock Would AI Choose? Alcon Inc. (ALC) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- Alcon Inc. (ALC) operates in vision care and surgical eye products, while Thermo Fisher Scientific Inc. (TMO) provides life sciences tools, diagnostics, and laboratory equipment.
- Recent market activity shows ALC shares trading near $70–72 with modest gains amid upcoming earnings, reflecting steady sector demand in eye care.
- TMO reported robust second-quarter 2026 results with 10% revenue growth to $11.99 billion and adjusted earnings per share (EPS) increases, supporting positive momentum in healthcare tools.
- Sector exposure differs: ALC focuses on ophthalmology end-markets, while TMO benefits from broader life sciences and research spending.
- Relative performance highlights trade-offs in stability versus growth catalysts, with both stocks influenced by healthcare spending trends and macroeconomic factors.
- Market sentiment remains neutral to constructive for both, driven by earnings visibility rather than speculative moves.
Introduction
Alcon Inc. (ALC) and Thermo Fisher Scientific Inc. (TMO) represent distinct segments within the healthcare sector, making them relevant for investors seeking exposure to medical devices and life sciences infrastructure. This comparison appeals to traders and portfolio managers evaluating relative performance, sector positioning, and resilience in a market environment shaped by innovation cycles and end-market demand. The analysis focuses on business models, recent price behavior, and observable factors that differentiate the two stocks without favoring either.
ALC Overview and Recent Performance
Alcon Inc. (ALC) develops, manufactures, and sells eye care products, including contact lenses, surgical equipment, and intraocular lenses through its vision care and surgical segments. The company, spun off from Novartis in 2019, maintains a global presence in ophthalmology markets. In recent weeks, ALC shares have traded in the $70–72 range with incremental gains amid positioning ahead of quarterly results. Sentiment has been supported by consistent demand for vision products and surgical innovations, though broader healthcare spending patterns and currency fluctuations have influenced short-term movements. Market activity reflects measured investor interest rather than pronounced volatility.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) supplies scientific instruments, reagents, diagnostics consumables, and laboratory services to research, pharmaceutical, and clinical laboratories worldwide. In recent weeks, the stock has shown resilience following strong second-quarter 2026 earnings, with revenue rising 10% year-over-year to $11.99 billion and adjusted EPS growth. Shares have traded around the $590–595 level with upward price action tied to execution in life sciences end-markets. Sentiment draws from sustained research spending and acquisition integration, tempered by typical sector valuation considerations and macroeconomic sensitivity.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across its platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance metrics tailored to current market conditions. Only those demonstrating strong historical statistics, risk-adjusted returns, and suitability for prevailing environments are featured in the trending section. Available bots span diverse styles with win rates often ranging from 55% to over 70% in backtested periods, alongside varying drawdown profiles and ticker coverage. This resource provides traders with data-driven options for automated strategies. Explore the curated list at the Trending AI Robots page for additional details.
Head-to-Head Comparison
Alcon Inc. (ALC) centers on specialized ophthalmology products with growth drivers tied to aging populations and elective procedures, whereas Thermo Fisher Scientific Inc. (TMO) offers diversified exposure across research tools and diagnostics with catalysts from pharmaceutical R&D (research and development) and clinical testing volumes. Recent momentum favors TMO following its earnings beat, while ALC exhibits more stable but less pronounced price action. Risk factors for ALC include procedure volume sensitivity and competition in devices; TMO faces exposure to research funding cycles and integration risks from acquisitions. Sector positioning places ALC in medical devices with narrower end-markets, contrasting TMO’s broader life sciences platform. Market sentiment reflects constructive but differentiated views, with TMO benefiting from reported results and ALC from steady fundamentals.
Tickeron AI Verdict
Based on observable factors such as earnings consistency, relative momentum, and end-market stability, Tickeron’s AI would currently assign a probabilistic edge to Thermo Fisher Scientific Inc. (TMO) over Alcon Inc. (ALC). TMO’s recent results and positioning in resilient research markets provide a measurable tilt, though outcomes remain subject to broader healthcare trends and execution variables.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a StrongBuy and TMO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 3 green FA rating(s).
- ALC’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- ALC’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 3 bullish, 4 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +5.72% price change this week, while TMO (@Medical Specialties) price change was +2.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.11%. For the same industry, the average monthly price growth was +8.49%, and the average quarterly price growth was +6.88%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.00%. For the same industry, the average monthly price growth was +7.63%, and the average quarterly price growth was +23.29%.
Reported Earning Dates
ALC is expected to report earnings on Nov 10, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.11% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-1.00% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ALC | TMO | ALC / TMO | |
| Capitalization | 36.1B | 218B | 17% |
| EBITDA | 2.54B | 12B | 21% |
| Gain YTD | -6.712 | 3.042 | -221% |
| P/E Ratio | 56.68 | 31.66 | 179% |
| Revenue | 10.6B | 46.3B | 23% |
| Total Cash | 1.66B | 4.06B | 41% |
| Total Debt | 5.25B | 42.5B | 12% |
ALC | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 92 | 81 | |
SMR RATING 1..100 | 88 | 61 | |
PRICE GROWTH RATING 1..100 | 51 | 10 | |
P/E GROWTH RATING 1..100 | 15 | 33 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is in the same range as ALC (32) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew similarly to ALC’s over the last 12 months.
TMO's Profit vs Risk Rating (81) in the Medical Specialties industry is in the same range as ALC (92) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew similarly to ALC’s over the last 12 months.
TMO's SMR Rating (61) in the Medical Specialties industry is in the same range as ALC (88) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew similarly to ALC’s over the last 12 months.
TMO's Price Growth Rating (10) in the Medical Specialties industry is somewhat better than the same rating for ALC (51) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew somewhat faster than ALC’s over the last 12 months.
ALC's P/E Growth Rating (15) in the Hospital Or Nursing Management industry is in the same range as TMO (33) in the Medical Specialties industry. This means that ALC’s stock grew similarly to TMO’s over the last 12 months.
| ALC | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 58% | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 53% | 2 days ago 64% |
| Momentum ODDS (%) | 2 days ago 63% | N/A |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 57% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 61% |
| Advances ODDS (%) | 4 days ago 57% | 4 days ago 62% |
| Declines ODDS (%) | 2 days ago 55% | 2 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 68% |
| Aroon ODDS (%) | 2 days ago 41% | 2 days ago 54% |
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.